| zotarolimus eluting stent vs bare-metal stent | No demonstrated result suggested MACE by 50% (not demonstrated) suggested angiographic restenosis by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | no data | | 4 yr mortality from all causes | no data | | cardiac death | no data | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 0.50 [0.34 0.73] | p=0.04 | 0 | 1197 | 1 | ENDEAVOR II, | | 2 yr MACE | no data | | target-vessel revascularization | no data | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | no data | | CABG | no data | | in-lesion binary restenosis | no data | | angiographic restenosis | 0.39 [0.26 0.59] | p=0.04 | 0 | 600 | 1 | ENDEAVOR II, | | All cause death | no data | | Stent thrombosis (any, end of follow up) | 0.43 [0.11 1.67] | p=1.00 | 0 | 1197 | 1 | ENDEAVOR II, | | 4y stent thrombosis (ARC) | no data | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs everolimus eluting stent | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.68 1.56] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr mortality from all causes | no data | | cardiac death | 0.80 [0.40 1.58] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | no data | | 2 yr MACE | no data | | target-vessel revascularization | 1.03 [0.70 1.51] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 1.17 [0.75 1.82] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | CABG | 0.76 [0.26 2.19] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | in-lesion binary restenosis | no data | | angiographic restenosis | no data | | All cause death | 0.59 [0.33 1.05] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | Stent thrombosis (any, end of follow up) | 1.55 [0.83 2.86] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4y stent thrombosis (ARC) | 1.55 [0.83 2.86] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | 4.04 [0.45 36.22] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | sub acute stent thrombosis (1-30 days) | 11.12 [0.61 201.27] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | late stent thrombosis (31days - 1year) | 2.53 [0.49 13.05] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs paclitaxel eluting stent | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 35% (not demonstrated) suggested MACE by 22% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 0.65 [0.47 0.90] | p=0.04 | 0 | 3452 | 3 | ENDEAVOR IV,ZEST AMI (vs PES),ZEST (vs PES), | | 4 yr mortality from all causes | no data | | cardiac death | 0.70 [0.33 1.49] | p=1.00 | 0 | 1467 | 1 | ENDEAVOR IV, | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 0.78 [0.64 0.96] | p=0.04 | 0 | 3452 | 3 | ENDEAVOR IV,ZEST AMI (vs PES),ZEST (vs PES), | | 2 yr MACE | no data | | target-vessel revascularization | 0.93 [0.68 1.28] | p=1.00 | 0 | 1685 | 2 | ENDEAVOR IV,ZEST AMI (vs PES), | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 0.83 [0.62 1.11] | p=1.00 | 0 | 3234 | 2 | ENDEAVOR IV,ZEST (vs PES), | | CABG | no data | | in-lesion binary restenosis | no data | | angiographic restenosis | no data | | All cause death | 0.88 [0.56 1.38] | p=1.00 | 0 | 3452 | 3 | ENDEAVOR IV,ZEST AMI (vs PES),ZEST (vs PES), | | Stent thrombosis (any, end of follow up) | 0.53 [0.16 1.70] | p=1.00 | 0 | 1985 | 2 | ZEST AMI (vs PES),ZEST (vs PES), | | 4y stent thrombosis (ARC) | 0.67 [0.27 1.64] | p=1.00 | 0 | 1467 | 1 | ENDEAVOR IV, | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs sirolimus eluting stent | No demonstrated result suggested angiographic restenosis by 333% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 0.77 [0.52 1.13] | p=1.00 | 0 | 2408 | 3 | ENDEAVOR III,ZEST (vs SES),ZEST AMI (vs SES), | | 4 yr mortality from all causes | no data | | cardiac death | no data | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 1.18 [0.89 1.57] | p=1.00 | 0 | 2411 | 3 | ENDEAVOR III,ZEST (vs SES),ZEST AMI (vs SES), | | 2 yr MACE | no data | | target-vessel revascularization | 1.24 [0.91 1.69] | p=1.00 | 0 | 1979 | 2 | ZEST (vs SES),ZEST AMI (vs SES), | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 1.84 [0.62 5.47] | p=1.00 | 0 | 432 | 1 | ENDEAVOR III, | | CABG | no data | | in-lesion binary restenosis | 2.75 [0.95 7.98] | p=1.00 | 0 | 376 | 1 | ENDEAVOR III, | | angiographic restenosis | 4.33 [1.01 18.62] | p=0.04 | 0 | 376 | 1 | ENDEAVOR III, | | All cause death | 0.81 [0.35 1.85] | p=1.00 | 0 | 2411 | 3 | ENDEAVOR III,ZEST (vs SES),ZEST AMI (vs SES), | | Stent thrombosis (any, end of follow up) | 0.80 [0.13 5.03] | p=1.00 | 0 | 2411 | 3 | ENDEAVOR III,ZEST (vs SES),ZEST AMI (vs SES), | | 4y stent thrombosis (ARC) | no data | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs bare-metal stent | No demonstrated result suggested MACE by 50% (not demonstrated) suggested angiographic restenosis by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | no data | | 4 yr mortality from all causes | no data | | cardiac death | no data | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 0.50 [0.34 0.73] | p=0.04 | 0 | 1197 | 1 | ENDEAVOR II, | | 2 yr MACE | no data | | target-vessel revascularization | no data | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | no data | | CABG | no data | | in-lesion binary restenosis | no data | | angiographic restenosis | 0.39 [0.26 0.59] | p=0.04 | 0 | 600 | 1 | ENDEAVOR II, | | All cause death | no data | | Stent thrombosis (any, end of follow up) | 0.43 [0.11 1.67] | p=1.00 | 0 | 1197 | 1 | ENDEAVOR II, | | 4y stent thrombosis (ARC) | no data | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs everolimus eluting stent | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.68 1.56] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr mortality from all causes | no data | | cardiac death | 0.80 [0.40 1.58] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | no data | | 2 yr MACE | no data | | target-vessel revascularization | 1.03 [0.70 1.51] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 1.17 [0.75 1.82] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | CABG | 0.76 [0.26 2.19] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | in-lesion binary restenosis | no data | | angiographic restenosis | no data | | All cause death | 0.59 [0.33 1.05] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | Stent thrombosis (any, end of follow up) | 1.55 [0.83 2.86] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4y stent thrombosis (ARC) | 1.55 [0.83 2.86] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | 4.04 [0.45 36.22] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | sub acute stent thrombosis (1-30 days) | 11.12 [0.61 201.27] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | late stent thrombosis (31days - 1year) | 2.53 [0.49 13.05] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs paclitaxel eluting stent | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 35% (not demonstrated) suggested MACE by 22% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 0.65 [0.47 0.90] | p=0.04 | 0 | 3452 | 3 | ENDEAVOR IV,ZEST AMI (vs PES),ZEST (vs PES), | | 4 yr mortality from all causes | no data | | cardiac death | 0.70 [0.33 1.49] | p=1.00 | 0 | 1467 | 1 | ENDEAVOR IV, | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 0.78 [0.64 0.96] | p=0.04 | 0 | 3452 | 3 | ENDEAVOR IV,ZEST AMI (vs PES),ZEST (vs PES), | | 2 yr MACE | no data | | target-vessel revascularization | 0.93 [0.68 1.28] | p=1.00 | 0 | 1685 | 2 | ENDEAVOR IV,ZEST AMI (vs PES), | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 0.83 [0.62 1.11] | p=1.00 | 0 | 3234 | 2 | ENDEAVOR IV,ZEST (vs PES), | | CABG | no data | | in-lesion binary restenosis | no data | | angiographic restenosis | no data | | All cause death | 0.88 [0.56 1.38] | p=1.00 | 0 | 3452 | 3 | ENDEAVOR IV,ZEST AMI (vs PES),ZEST (vs PES), | | Stent thrombosis (any, end of follow up) | 0.53 [0.16 1.70] | p=1.00 | 0 | 1985 | 2 | ZEST AMI (vs PES),ZEST (vs PES), | | 4y stent thrombosis (ARC) | 0.67 [0.27 1.64] | p=1.00 | 0 | 1467 | 1 | ENDEAVOR IV, | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs sirolimus eluting stent | No demonstrated result Stent thrombosis (any, end of follow up) by 315% (harmful effect) suggested 2 yr Death (all cause) by 61% (not demonstrated) suggested 2 yr MACE by 119% (not demonstrated) suggested 2 yr TLR by 266% (not demonstrated) suggested target lesion revascularisation by 233% (not demonstrated) suggested angiographic restenosis by 333% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | 1.61 [1.03 2.51] | p=0.04 | 0 | 2333 | 1 | SORT-OUT-3, | | myocardial infarction (fatal and non fatal) | 0.92 [0.64 1.34] | p=1.00 | 0 | 4523 | 3 | ENDEAVOR III,ZEST (vs SES),SORT-OUT-3, | | 4 yr mortality from all causes | no data | | cardiac death | 1.51 [0.73 3.13] | p=1.00 | 0 | 2333 | 1 | SORT-OUT-3, | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 1.17 [0.87 1.59] | p=1.00 | 0 | 2193 | 2 | ENDEAVOR III,ZEST (vs SES), | | 2 yr MACE | 2.19 [1.58 3.04] | p=0.04 | 0 | 2333 | 1 | SORT-OUT-3, | | target-vessel revascularization | 1.21 [0.88 1.68] | p=1.00 | 0 | 1761 | 1 | ZEST (vs SES), | | 2 yr TLR | 3.66 [2.23 6.01] | p=0.04 | 0 | 2333 | 1 | SORT-OUT-3, | | 4 yr TLR | no data | | target lesion revascularisation | 3.33 [1.87 5.93] | p=0.04 | 0 | 2765 | 2 | ENDEAVOR III,SORT-OUT-3, | | CABG | no data | | in-lesion binary restenosis | 2.75 [0.95 7.98] | p=1.00 | 0 | 376 | 1 | ENDEAVOR III, | | angiographic restenosis | 4.33 [1.01 18.62] | p=0.04 | 0 | 376 | 1 | ENDEAVOR III, | | All cause death | 1.23 [0.71 2.11] | p=1.00 | 0 | 4526 | 3 | ENDEAVOR III,ZEST (vs SES),SORT-OUT-3, | | Stent thrombosis (any, end of follow up) | 4.15 [1.39 12.39] | p=0.04 | 0 | 4526 | 3 | ENDEAVOR III,ZEST (vs SES),SORT-OUT-3, | | 4y stent thrombosis (ARC) | no data | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs bare-metal stent | No demonstrated result suggested MACE by 50% (not demonstrated) suggested angiographic restenosis by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | no data | | 4 yr mortality from all causes | no data | | cardiac death | no data | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 0.50 [0.34 0.73] | p=0.04 | 0 | 1197 | 1 | ENDEAVOR II, | | 2 yr MACE | no data | | target-vessel revascularization | no data | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | no data | | CABG | no data | | in-lesion binary restenosis | no data | | angiographic restenosis | 0.39 [0.26 0.59] | p=0.04 | 0 | 600 | 1 | ENDEAVOR II, | | All cause death | no data | | Stent thrombosis (any, end of follow up) | 0.43 [0.11 1.67] | p=1.00 | 0 | 1197 | 1 | ENDEAVOR II, | | 4y stent thrombosis (ARC) | no data | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs everolimus eluting stent | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 1.03 [0.68 1.56] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr mortality from all causes | no data | | cardiac death | 0.80 [0.40 1.58] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | no data | | 2 yr MACE | no data | | target-vessel revascularization | 1.03 [0.70 1.51] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 1.17 [0.75 1.82] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | CABG | 0.76 [0.26 2.19] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | in-lesion binary restenosis | no data | | angiographic restenosis | no data | | All cause death | 0.59 [0.33 1.05] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | Stent thrombosis (any, end of follow up) | 1.55 [0.83 2.86] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4y stent thrombosis (ARC) | 1.55 [0.83 2.86] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | 4.04 [0.45 36.22] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | sub acute stent thrombosis (1-30 days) | 11.12 [0.61 201.27] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, | | late stent thrombosis (31days - 1year) | 2.53 [0.49 13.05] | p=1.00 | 0 | 2292 | 1 | RESOLUTE All comers, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs paclitaxel eluting stent | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 35% (not demonstrated) suggested MACE by 24% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 0.65 [0.47 0.90] | p=0.04 | 0 | 3234 | 2 | ENDEAVOR IV,ZEST (vs PES), | | 4 yr mortality from all causes | no data | | cardiac death | 0.70 [0.33 1.49] | p=1.00 | 0 | 1467 | 1 | ENDEAVOR IV, | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 0.76 [0.62 0.94] | p=0.04 | 0 | 3234 | 2 | ENDEAVOR IV,ZEST (vs PES), | | 2 yr MACE | no data | | target-vessel revascularization | 0.91 [0.65 1.27] | p=1.00 | 0 | 1467 | 1 | ENDEAVOR IV, | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 0.83 [0.62 1.11] | p=1.00 | 0 | 3234 | 2 | ENDEAVOR IV,ZEST (vs PES), | | CABG | no data | | in-lesion binary restenosis | no data | | angiographic restenosis | no data | | All cause death | 0.83 [0.53 1.32] | p=1.00 | 0 | 3234 | 2 | ENDEAVOR IV,ZEST (vs PES), | | Stent thrombosis (any, end of follow up) | 0.67 [0.19 2.37] | p=1.00 | 0 | 1767 | 1 | ZEST (vs PES), | | 4y stent thrombosis (ARC) | 0.67 [0.27 1.64] | p=1.00 | 0 | 1467 | 1 | ENDEAVOR IV, | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| zotarolimus eluting stent vs sirolimus eluting stent | No demonstrated result suggested angiographic restenosis by 333% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 0.78 [0.53 1.16] | p=1.00 | 0 | 2190 | 2 | ENDEAVOR III,ZEST (vs SES), | | 4 yr mortality from all causes | no data | | cardiac death | no data | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 1.17 [0.87 1.59] | p=1.00 | 0 | 2193 | 2 | ENDEAVOR III,ZEST (vs SES), | | 2 yr MACE | no data | | target-vessel revascularization | 1.21 [0.88 1.68] | p=1.00 | 0 | 1761 | 1 | ZEST (vs SES), | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | 1.84 [0.62 5.47] | p=1.00 | 0 | 432 | 1 | ENDEAVOR III, | | CABG | no data | | in-lesion binary restenosis | 2.75 [0.95 7.98] | p=1.00 | 0 | 376 | 1 | ENDEAVOR III, | | angiographic restenosis | 4.33 [1.01 18.62] | p=0.04 | 0 | 376 | 1 | ENDEAVOR III, | | All cause death | 0.82 [0.30 2.23] | p=1.00 | 0 | 2193 | 2 | ENDEAVOR III,ZEST (vs SES), | | Stent thrombosis (any, end of follow up) | 2.82 [0.27 29.37] | p=1.00 | 0 | 2193 | 2 | ENDEAVOR III,ZEST (vs SES), | | 4y stent thrombosis (ARC) | no data | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
